denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: F. Hoffmann-La Roche Ltd
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Lymphomas, Clinical Practice (Health Services and Quality), Education, Diseases, Treatment Considerations, Lymphoid Malignancies
Hematology Disease Topics & Pathways:
Lymphomas, Clinical Practice (Health Services and Quality), Education, Diseases, Treatment Considerations, Lymphoid Malignancies
Friday, December 6, 2024: 11:00 AM-2:00 PM
Marriott Grand Ballroom 2-4
(Marriott Marquis San Diego Marina)
Chair:
Wendy Osborne, MD, Newcastle Hospitals NHS Trust
Disclosures:
Osborne: Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria; Kite Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees; Astra Zeneca: Honoraria; Novartis: Honoraria; Kyowa Kirin: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees; Servier: Membership on an entity's Board of Directors or advisory committees; MSD: Membership on an entity's Board of Directors or advisory committees; Beigene: Membership on an entity's Board of Directors or advisory committees; Autolus: Membership on an entity's Board of Directors or advisory committees; Sobi: Membership on an entity's Board of Directors or advisory committees; Syneos: Membership on an entity's Board of Directors or advisory committees.
Speakers:
Gareth P. Gregory, MBBS(Hons), PhD, FRACP, FRCPA, School of Clinical Sciences at Monash Health, Monash University
,
Natacha Bolaños, ARRAY(0xdf38050)
and
Gilles Salles, MD, PhD, Lymphoma Service Chief, Memorial Sloan Kettering Cancer Center
Disclosures:
Gregory: Merck, BeiGene (to institute, not individual): Research Funding; Roche, Merck: Speakers Bureau; Merck, Amgen, Roche, Novartis, BMS, Clinigen, Gilead, Prelude Therapeutics: Membership on an entity's Board of Directors or advisory committees.
Medscape has identified several key focus areas to address during the Symposium taking place at ASH 2024 on the 6th of December in San Diego:
- Understanding treatment goals and treatment options for patients with diffuse large B-cell lymphoma (DLBCL) at first relapse where transplant and CAR T-cell therapy are not a suitable option
- Consideration of the patient perspective of living with relapsed or refractory (R/R) DLBCL and how to effectively communicate with patients to ensure shared decision-making when selecting therapy
- Appreciation of the value of bispecific antibodies for the current management of R/R DLBCL and considerations for earlier use at first relapse
See more of: Friday Satellite Symposia